FDA Generics Office To Revise BCS Waiver Guidance Under Science Director
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD